Intact Investment Management Inc. Has $4.74 Million Stock Position in The Clorox Company (NYSE:CLX)

Intact Investment Management Inc. grew its position in The Clorox Company (NYSE:CLX - Free Report) by 7,950.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,200 shares of the company's stock after buying an additional 31,800 shares during the period. Intact Investment Management Inc.'s holdings in Clorox were worth $4,741,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Integral Investment Advisors Inc. grew its holdings in shares of Clorox by 4.1% in the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock valued at $279,000 after buying an additional 67 shares during the period. Sonora Investment Management Group LLC grew its holdings in shares of Clorox by 2.5% in the 1st quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock valued at $433,000 after buying an additional 72 shares during the period. Sound View Wealth Advisors Group LLC grew its holdings in shares of Clorox by 6.1% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company's stock valued at $218,000 after buying an additional 77 shares during the period. Wedbush Securities Inc. grew its holdings in shares of Clorox by 1.2% in the 4th quarter. Wedbush Securities Inc. now owns 7,624 shares of the company's stock valued at $1,238,000 after buying an additional 94 shares during the period. Finally, Aviance Capital Partners LLC grew its holdings in shares of Clorox by 3.2% in the 4th quarter. Aviance Capital Partners LLC now owns 3,180 shares of the company's stock valued at $516,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Trading Down 0.1%

Shares of NYSE:CLX opened at $120.81 on Friday. The company's 50-day moving average price is $133.11 and its two-hundred day moving average price is $146.77. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44. The Clorox Company has a one year low of $120.33 and a one year high of $171.37. The stock has a market capitalization of $14.89 billion, a PE ratio of 21.69, a price-to-earnings-growth ratio of 2.73 and a beta of 0.54.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period last year, the firm earned $1.71 earnings per share. On average, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Analysts Set New Price Targets

CLX has been the subject of several research analyst reports. Barclays decreased their price target on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a report on Wednesday, May 7th. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Morgan Stanley reduced their target price on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. UBS Group reduced their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Finally, Citigroup reduced their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $151.23.

Insider Activity

In other news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.57% of the stock is owned by insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.